MaxCyte has achieved another milestone, securing a sixth commercial licence for its Flow Electroporation technology with leading genome editing company Editas Medicine. This new non-exclusive clinical and commercial licence agreement allows Editas to use MaxCyte’s technology and its ExPERT instruments in the development and commercialisation of up to five therapies (sickle cell/beta thalassemia programme EDIT-301 and four immuno-oncology programmes). MaxCyte is eligible for development and approval milestones and sales-based payments in addition to other licensing fees, and revenue from consumables sales. The deal with Editas reinforces MaxCyte’s position as the key enabler for gene edited (including CRISPR-based) therapies, further increasing confidence in our £195m (341p/share) valuation.
07 Oct 2019
Editas deal marks sixth commercial licence
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Editas deal marks sixth commercial licence
MaxCyte, Inc. (MXCT:LON) | 345 0 0.0% | Mkt Cap: 359.2m
- Published:
07 Oct 2019 -
Author:
Mick Cooper PhD -
Pages:
3
MaxCyte has achieved another milestone, securing a sixth commercial licence for its Flow Electroporation technology with leading genome editing company Editas Medicine. This new non-exclusive clinical and commercial licence agreement allows Editas to use MaxCyte’s technology and its ExPERT instruments in the development and commercialisation of up to five therapies (sickle cell/beta thalassemia programme EDIT-301 and four immuno-oncology programmes). MaxCyte is eligible for development and approval milestones and sales-based payments in addition to other licensing fees, and revenue from consumables sales. The deal with Editas reinforces MaxCyte’s position as the key enabler for gene edited (including CRISPR-based) therapies, further increasing confidence in our £195m (341p/share) valuation.